Saint-Gobain Life Sciences and denovoMATRIX Announce Collaboration to Optimize New Product Development

Saint-Gobain Life Sciences and denovoMATRIX Announce Collaboration to Optimize New Product Development
November 9, 2021 By Cade Hildreth (CEO)

DRESDEN, Germany, 9 November, 2021 / BioInformant / — denovoMATRIX GmbH and Saint-Gobain Life Sciences have entered into a Master Service Agreement focused on optimizing the performance of new products in development for adherent cell culture and harvest for autologous therapies. The relationship will further explore the synergy of consumable products from both parties and their positive effects for the therapeutic market.

Dejan Hušman, CEO of denovoMATRIX, commented “Integration of the latest technological innovations in the Cell Therapy space is essential to bring therapies to clinical trials and the mainstream as soon as possible. We are delighted to partner with Saint-Gobain Life Sciences to bring our technology platform to bear on the most critical challenges in autologous cell manufacturing.”

“We have found that the user experience is just as important as the product performance in new product development,” said Benjamin Le Quere, General Manager for Saint-Gobain Life Sciences’ Bioprocess Solutions Business Unit. “denovoMatrix is an ideal partner for us because of the technical capabilities they bring to this partnership. The feedback we receive from them will help ensure that our products are achieving the desired results, while being user-friendly for our customers.”

The companies expect to utilize both research and development and laboratory facilities from both companies, including in the United States and Germany. The companies will begin collaborating immediately.

About denovoMATRIX GmbH
denovoMATRIX is an extracellular matrix engineering company that enables the acceleration of cell-based therapies and development in stem cell research. The company leverages chemical synthesis, stem cell biology and design thinking to build a platform of biomaterials which address major life science challenges. By providing both cell-based therapy companies and translational researchers with solutions, denovoMATRIX is at the forefront of innovation in biomaterials.

For more information, visit: https://www.denovomatrix.com/
 

Contact:
denovoMATRIX GmbH
Dr. Dejan Hušman Tatzberg 47/49
01307 Dresden
mail@denovomatrix.com

About Saint-Gobain Life Sciences

Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical and pharmaceutical customers around the world.

Saint-Gobain Life Sciences is part of Saint-Gobain Group, which designs, manufactures and distributes materials and solutions for the construction, mobility, healthcare and other industrial application markets.

€38.1 billion in sales in 2020 More than 167,000 employees, located in 70 countries Committed to achieving Carbon Neutrality by 2050

For more information, www.saint-gobain.com

And visit: https://www.celltherapy.saint-gobain.com

Contact:
Saint-Gobain Life Sciences
Katy Oroszi
Marketing Communications Manager
Katy.oroszi@saint-gobain.com